lnterferons in Haematologic Malignancies: [HEMATOLOJİK MALİGNENSİLERDE İNTERFERONLAR]

Can Boğa; Yalçın Kepekçi

doi:10.58600/eurjther.19910102-606

Authors

Can Boğa Gaziantep Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dal
Yalçın Kepekçi Gaziantep Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dal

DOI:

https://doi.org/10.58600/eurjther.19910102-606

Keywords:

Interferon, haematologic malignancy, hairycell leukemia, multiple myeloma, myelogenous leukemia, lymphoma

Abstract

lnterferons are new therapeutic agents which are widely used in some medical fields. in this rewivew the therapeutic effects of interferons were discussed on haematologic malignencies such as hair-cell leukemia, multiple myeloma, non Hodgin lymphoma, chronic myelogenous leukemia according to literature obtained from last ten years.

Metrics

Metrics Loading ...

References

Bordan CE: Progress toward therapeutic application of interferons. Cancer 54:2770-2776.

Silver KBH, Salinas AF, Kongs S: 1.İnterferon congresses, 2. Cancer-treatment-congresses, Toronto. Role of interferons in immune regulation. Published by mes medical education services (Canada) ine a medicine group 1986, p. 1-7

Stevenson HR: Biotechnology and the development of interferon. 14th lnternational cancer congress. Budapest 22-27, August, 1986.

Spiegel JR: Alpha interferon dosage, toxicity and antibody formation. 1.interferon-Congresses. g. Cancer treatment-congresses. Toronto, Canada p:17, 1986.

Border S, Bunn PA, Jaffe ES, et al. T-cell lympho proliferative syndrome associated with human T-cell leukemia lymphoma virus. Ann lntern Med. 100: 543-57.

Salmon ES, Hamburger WA, Soehnlen B, et al. Quantitation of differential sensitivity of humantumor stem cells to anticancer drugs. N Engl J Med 298:24, 1321-1327, 1978.

Waldmann TA, Korsmayer SJ, Bakhshi A, et ai: Molucular genetic analys is of human ıymphhoid neoplasms. lmmunoglobulin gen es and the c-myc oncogene. Ann lntern Med 102: 497-51 O, 1985.

Freidman MR. Growth fı:ıctors and oncogenes. 1. interferon Congresses. 2. cancer-treatmentcongresses. ı. Silver Hulbert Keyes belfort. 1986.

Fresa KL, Murasko DM: Role of natural killer cells in the mechanism of the antitumor effect of interferon on moloney sarcoma virus, transformed cells. Cancer Res 1986: 46: 81-8.

Wadler S, Schwartz LE: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignencies. A review. Cancer Res 50, June 15, 3473-3486, 1990.

Slater LM, Wetzel MW, Cesario T: Combined interferon-antimetabolite therapy of murine L 1210 leukemia. Cancer (Phila) 48: 5-9, 1981.

Balkwill FR and Moodie EM: Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system Cancer Res, 44: 904-908, 1984.

Foon AK: lnterferon therapy lymphoproliferative disorders. Seminars in Hematology, Vol 23(3) 10-13, 1986.

Golomp HM, Catovsky D, Golde DW: Hairy cel leukemia. Ann lntern Med 99, 485-6, 1983.

Queseda JR, Reuben J, Mannig JT, et al: Alpha interferon for induction of remission in hairy celi ıeukemia. N Engl J Med. 310: 15-18, 1984.

Quaseda RJ, Gutterman UJ. Alpha interferons in B-cell neoplasm Br J Hematology 64, 639-46, 1986.

Rosenblatt JD, Golde DW, Wachsman WL, et al: A second isolate of HTL V-11 associated with atypical hairy celi leukemia. N Engl J Engl J Med 315: 372-77, 1986.

Glaspy AJ, Jacobs DA, Golde WD: Evolving therapy of hairy cell leukemia. Cancer 59: 652-657, 1987.

Vannorman AS; Nagorney DM; Martin JK, et al: Splenectomy tor hairy cell leukemia. 57: 644-8, 1986.

Golomp HM, Vardiman JW: Response to splenectomy in 65 patients with hairy cell leukemia. Blood 61:349-352, 1983.

Degos L: Alpha-İnterferon in hairy cell leukemia: 14th lnternational Cancer Congress, Budapest. 22-27, August. 1986.

Queseda JR, Keating MJ, Libshitz Hl, et al: Bone lnvolvement in hairy cell leukemia. Am J Med 74: 228-231, 1983.

Sakson A, Stevens RH, Golde DW: T.Lenfosit variant of hairy cell lekemia. Ann lntern Med 88: 323-326, 1978.

Talpaz M, McCredie KB, Rosenblum MG, et al: chronic myelogenous leukemia. Blood. 62: 689-992, 1986.

Talpaz M, Kantarjian H, McCredie K, et al: Therapy of Chronic myelogenous leukemia. Cancer 59: 644-667, 1987.

Gastl G, Aulitzky W, Tilg H, et al: Minimal interferon-alpha doses tor hairy cell leukemia. Cancer 59: 602, 1987.

Mellsted H, Bjorkholm M, Johansson B: lnterferon therapy in myelomatosis Lancet 1: 245-8, 1979.

Thompson JA, Fefer A: lnterferon in the treatment of hairy cell leukemia. Cancer 59: 605, 1987.

Gale AP, Foon KA: Chronic lymphocytic leukemia Ann. ıntern Med 102: 596-602, 1986.

Merigen TC, Sikora K, Breeden JH, et al: Preliminary observations on the effect of human leukocyte interferon on non-hodgin ıymphoma. N Engl J Med. 299: 1449-1453, 1978.

Talpaz M, Kentarjian UM, McCredie KB, et al: Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood:69: 1280-8, 1987.

Brouty-Baye D, Cheng EY, Chen BL: Association of phenotypic reversion of transformed cells inuced bey interferon with morphological and biochemicaı changes in the cytoskeleton. Cancer Aes 41: 4174-6, 1981.

Foon KA, Sherwin SA, Abrams PG, et al. Treatment of advanced non-hodgin lymphoma with recombinant leukocyte A interferon. N Engl J Med. 311: 1148-1152, 1984.

Bunn PA, Foon KA, lhde DC, et al. Aecornbinant leukocyte A interferon An active agent in advanced cutaneus T-cell ıymphoma. Ann lnt Med 109: 484-487, 1984.

Bunn AP: Aecombinant alfa-2 a is an active agent in advanced cutaneus T-cell ıymphomas. 14th international cancer congress. Budapest. 22-27, August, 1986.

Steis GA, Foon AK, Longo LD: Current and future uses of recombinant interferon alpha in the treatment of low-grade non-hodgine lymphoma. Cancer 59: 658-663, 1987.

Alimena G, Morra Em, Lazzarino M, et al: lnterferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 72:642-7, 1988.

Dinarello CA and Mier JW: Lymphokines. N Engl J Med, 317: 940-945, 1987.

Trown PW, Kramer MJ, Dennin AA, et al: Antibodies to luman leukocyte interferon. in cancer patients lancet 1: 81-4, 1883.

Spiegel AJ, Spicehandler JA, Jacobss, et al: Low insidance of serum neutralizing factors in patients receiving recombinant alfa-2b interferon Am J Med 80: 223-8, 1986.

Thompson JA, Kidd P, Aubin E, et al: Very low dose alpha 2b interferon for the treatment of hairy celi leukemia. Blood 73: 1440, 1989.